drugset / Trial / NCT07076407
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Timeline
- Start
- 2025-07-08
- Primary completion
- 2027-05
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azetukalner | Small molecule | 20 mg | Oral |